

Question for written answer E-005018/2025
to the Commission
Rule 144
Adam Jarubas (PPE)

Subject: Exemptions for the life-science value chain in upcoming EU US trade measures

The life sciences sector, which supplies critical technologies and products to the medical, diagnostic, and medical device sectors, is a strategic pillar of Europe's resilience in health, crisis preparedness, and competitiveness. It is globally interconnected, and tariffs risk undermining Europe's strategic autonomy and patients' access to essential products.

Recent discussions between stakeholders and policymakers highlighted the need for clarity on exemptions for the entire life-science value chain, including medicines, therapeutics, devices, diagnostics and their upstream suppliers, from any retaliatory measures in the context of EU-US trade relations, with a priority for a zero-for-zero tariff scenario. While there is broad support for exempting these categories, the criteria and scope for such exemptions remain undefined.

Could the Commission please answer the following questions:

1. How does the Commission intend to define exemptions for the life-science value chain, in the context of upcoming trade measures and tariff frameworks?
2. Will the Commission commit to exempting not only finished products within the healthcare sectors, but also upstream materials and components essential to the manufacture, supply chain of half-finished goods, consumables, hardware and use of those products?
3. What steps are being taken to ensure that these exemptions are aligned with Europe's objectives for health resilience, strategic autonomy, and competitiveness?

Submitted: 18.12.2025